Lymph node staging in non-small cell lung cancer: Evaluation by [18F]FDG positron emission tomography (PET)

Thorax

Volumn 52, Issue 5, 1997, Pages 438-441

  Guhlmann, Albrecht ^a   Storck, Martin ^a   Kotzerke, Jörg ^a   Moog, Florian ^a   Sunder Plassmann, Ludger ^a   Reske, Sven N ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

FDG PET; Lung cancer; Lymph node staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0030923823     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.5.438     Document Type: Article

References (39)

1. Bains MS. Surgical treatment of lung cancer. Chest 1991; 100:826-37.
2. Mountain CF. Surgery for stage IIIa-N2 non-small cell lung cancer. Cancer 1994;73:2589-98.
3. Armstrong P, Vincent JM. Staging non-small cell lung cancer. Clin Radial 1993;48:1-10.
4. Armstrong P. Preoperative computed tomographic scanning for staging lung cancer (editorial). Thorax 1994;49:941-3.
5. Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology, 1991; 178:705-13.
6. McLoud TC, Bourgouin, PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JAO, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;182:319-23.
7. White PG, Adams H, Crane MD, Butchard EG. Preoperative staging of carcinoma of the bronchus: can computed tomographic scanning reliably identify stage III tumours? Thorax 1994;49:951-7.
8. Warburg O. The metabolism of tumors. 1st ed. New York: Richard R Smith, 1931:129-69.
9. Nolop KB, Rhodes CG, Brudin LH, Beaney RP, Krausz T, Jones T, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987;60:2682-9.
10. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990;31:1927-33.
11. Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992;184:441-4.
12. 18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17:582-9.
13. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487-90.
14. Rege SD, Hoh CK, Glaspy JA, Aberle DR, Dahlbom M, Razavi MK, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993;72:82-90.
15. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 1993;104:997-1002.
16. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994:344:1265-6.
17. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994;191:379-82.
18. Inoue T, Kim EE, Komaki R, Wong FCL, Bassa P, Wong WH, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995:36:788-93.
19. Frank A, Lefkowitz D, Jaeger S, Gobar L, Sunderland J, Gupta N, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 1995; 32:1495-512.
20. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130-9.
21. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995;108:441-6.
22. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation Radiology 1994;191: 371-7.
23. Scott WJ, Schwabe JL, Gupta NC, Dewan NA, Reeb SD, Sugimoto JT, and the members of the PET-lung tumor study group. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F] fluorodeoxyglucose. Ann Thorac Surg 1994:58:698-703.
24. Scott WJ, Gobar LS, Hauser LG, Sunderland JJ, Dewan NA, Sugimoto JT. Detection of scalene lymph node metastases from lung cancer. Positron emission tomography. Chest 1995;107:1174-6.
25. World Health Organization. International histological classification of tumours. Berlin: Springer-Verlag, 1991.
26. UICC. TNM classification of malignant tumours. Berlin: Springer-Verlag, 1987:69-73.
27. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978;76:832-9.
28. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, et al. Role of whole-body FDG-PET in nodal staging of lymphoma. Radiology (in press).
29. Stollfuss JC, Glatting G, Friess H, Kocher F, Beger HG, Reske SN. 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995;195:339-14.
30. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Conto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330: 153-8.
31. Kerr KM, Lamb D, Wathen CG, Walker WS, Douglas NJ. Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging. Thorax 1992;47:337-41.
32. Arita T, Kuramitsu T, Kawamura M, Matsumoto T, Matsunaga N, Sugi K, et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995;50:1267-9.
33. Som P, Atkins HL, Bandophadhyah D, Fowler JS, Mac-Gregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): non-toxic tracer for rapid tumor detection. J Nucl Med 1980;21:670-5.
34. Reske SN, Bares R, Büll U, Guhlmann A, Moser E, Wannenmacher MF. Klinische Wertigkeit der Positronen-Emissions-Tomographie (PET) bei onkologischen Fragestellungen: Ergebnisse einer interdisziplinären Konsensuskonferenz. Nuklearmedizin 1996;35:42-52.
35. Sazon DAD, Santiago SM, Hoo GWS, Khonsary A, Brown C, Mandelkern M, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417-21.
36. 18FDG in patients with bronchogenic carcinoma. Chest 1995;108:1617-21.
37. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996,37:1428-36.
38. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994;35: 1771-6.
39. Kubota R, Yamada S, Kubota K, Ishikawa K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1872-80.